In drug development, where you have a very long sequence of filters searching for molecules that treat diseases, the most high-leverage way to reduce R&D costs per *successful* drug is to increase the predictive validity of the early screening steps.
-
-
Unless I'm misinformed, this isn't a case where novel screening methods are mistrusted because they have a poor track record.
Show this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
It's true that drug discovery has been trending towards bigger and bigger screens for decades, without reducing R&D costs per successful drug at all. ("Eroom's Law.") But I think this is adequately explained by poor predictive validity.
Show this thread -
In order to test whether your bigger, cheaper screen will help select better drug candidates, you have to measure its ability to predict outcomes at much later stages of the development process.
Show this thread - 11 more replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.